An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Dokument öffnen (4.7MB)Art der Hochschulschrift
DissertationPrüfungsdatum
19.03.2010Datum der Veröffentlichung
24.09.2010Erstgutachter
Abken, HinrichZweitgutachter
Mohr, KlausMetadaten
Zur Langanzeige
Zitierbare Links 
Inhalt
Classical Hodgkin’s lymphoma is one of the most curable cancers today. However, non-responders, tumour relapses and long-term toxicities of the treatment make it necessary to look for alternative drugs. In this study, we have generated a novel immunocytokine that aims to overcome the misguided TH2 immune response in Hodgkin’s lymphoma by targeting CD30 on the surface of the malignant Hodgkin-Reed-Sternberg cells, and by combining IL-2 and IL-12 domains in one molecule. This immunocytokine induces resting natural killer cells to specific lysis of CD30⁺ tumour cells, exhibits superior cytokine activity compared to immunocytokines with a single cytokine domain, and inhibits tumour growth in immunocompetent mice.
Schlagwörter
Pharmakologie, Immuntherapie, Krebsmittel, Fusionsprotein, Antikörperhaltiges Arzneimittel, Zytokine, pharmacology, immunotherapy, anti-cancer drug, fusion protein, antibody-containing drug, cytokines
Klassifikation (DDC)
570 Biowissenschaften, Biologie 610 Medizin, GesundheitISBN/ISSN zugehöriger Publikation(en)
978-3-86853-433-7Zuther, Martin: An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity. - Bonn, 2010. - Dissertation, Rheinische Friedrich-Wilhelms-Universität Bonn.
Online-Ausgabe in bonndoc: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829
Online-Ausgabe in bonndoc: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829
@phdthesis{handle:20.500.11811/4588,
urn: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829,
author = {{Martin Zuther}},
title = {An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
year = 2010,
month = sep,
note = {Classical Hodgkin’s lymphoma is one of the most curable cancers today. However, non-responders, tumour relapses and long-term toxicities of the treatment make it necessary to look for alternative drugs. In this study, we have generated a novel immunocytokine that aims to overcome the misguided TH2 immune response in Hodgkin’s lymphoma by targeting CD30 on the surface of the malignant Hodgkin-Reed-Sternberg cells, and by combining IL-2 and IL-12 domains in one molecule. This immunocytokine induces resting natural killer cells to specific lysis of CD30⁺ tumour cells, exhibits superior cytokine activity compared to immunocytokines with a single cytokine domain, and inhibits tumour growth in immunocompetent mice.},
url = {https://hdl.handle.net/20.500.11811/4588}
}
urn: https://nbn-resolving.org/urn:nbn:de:hbz:5N-21829,
author = {{Martin Zuther}},
title = {An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity},
school = {Rheinische Friedrich-Wilhelms-Universität Bonn},
year = 2010,
month = sep,
note = {Classical Hodgkin’s lymphoma is one of the most curable cancers today. However, non-responders, tumour relapses and long-term toxicities of the treatment make it necessary to look for alternative drugs. In this study, we have generated a novel immunocytokine that aims to overcome the misguided TH2 immune response in Hodgkin’s lymphoma by targeting CD30 on the surface of the malignant Hodgkin-Reed-Sternberg cells, and by combining IL-2 and IL-12 domains in one molecule. This immunocytokine induces resting natural killer cells to specific lysis of CD30⁺ tumour cells, exhibits superior cytokine activity compared to immunocytokines with a single cytokine domain, and inhibits tumour growth in immunocompetent mice.},
url = {https://hdl.handle.net/20.500.11811/4588}
}
Die folgenden Nutzungsbestimmungen sind mit dieser Ressource verbunden:
